WELCHER ANDREW A.,BOEDIGHEIMER MICHAEL J.,CHUNG JAMES B.
申请号：
NZ62532412
公开号：
NZ625324A
申请日:
2012.11.21
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is the use of a monoclonal anti-human interferon gamma (anti-huIFN-&gamma) antibody in the manufacture of a medicament for treating a disease wherein the medicament is for use in a method comprising administering the anti-huIFN-&gamma at a dose of at least about 20 milligrams to not more than about 200 milligrams, wherein: - the anti-huIFN-&gamma antibody has a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 34 (SYWIG), a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 35 (IIYPGDSDTRYSPSFQG), a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 36 (GSYFYFDL), a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 38 (RASQSVSSSYLA), a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 41 (GASSRAT), and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 43 (QRSGGSSFT) and - the disease is selected from the group consisting of systemic lupus erythematosus (SLE), Graves&rsquo disease, Sjogren&rsquos syndrome, inflammatory bowel diseases including Crohn&rsquos disease and ulcerative colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, dermatomyositis, polymyositis, type I diabetes, sarcoidosis, and hemophagocytic lymphohistiocytosis.
